ABSTRACT
Purpose
To identify whether chemoradiotherapy improves survival in patients with stage T3–4N0M0 nasopharyngeal carcinoma (NPC).
Materials and methods
The data of patients with stage T3–4N0M0 NPC were extracted from the Surveillance, Epidemiology, and End Results database between 2004 and 2016. The patients were divided into radiotherapy and chemoradiotherapy groups. Overall survival (OS) and cancer‐specific survival (CSS) were assessed using the Kaplan–Meier method and propensity score matching (PSM) analyses.
Results
We examined 496 patients: 88 who received radiotherapy and 408 who received chemoradiotherapy. Before PSM, chemoradiotherapy was associated with a better 5‐year OS (52.58% vs. 38.13%; P=0.005) and similar CSS (63.62% vs. 59.26%; P=0.196) compared to those associated with radiotherapy. However, chemoradiotherapy was not an independent prognostic factor for OS [hazard ratio (HR)=0.95, 95% confidence interval (CI): 0.68–1.32; P=0.760] or CSS (HR=1.02, 95% CI: 0.66–1.56; P=0.935). After PSM, similar OS (45.15% vs. 42.78%; P=0.626) and CSS (58.22% vs. 60.37%; P=0.730) were found between the radiotherapy and chemoradiotherapy groups.
Conclusion
Radiotherapy and chemoradiotherapy are associated with similar OS and CSS in patients with stage T3–4N0M0 NPC.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.